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http://www.retrovirology.com/content/11/1/93RESEARCH Open AccessADAR1 enhances HTLV-1 and HTLV-2 replication
through inhibition of PKR activity
Anne Cachat1,2,3,4,5, Sandrine Alais1,2,3,4,5†, Sébastien Alain Chevalier1,2,3,4,5†, Chloé Journo1,2,3,4,5, Floriane Fusil3,4,5,6,
Hélène Dutartre1,2,3,4,5, Adrien Boniface1,2,3,4,5,7, Nga Ling Ko8, Antoine Gessain8, François-Loïc Cosset3,4,5,6,
Rodolphe Suspène9, Jean-Pierre Vartanian9 and Renaud Mahieux1,2,3,4,5*Abstract
Background: The role of innate immunity in general and of type I interferon (IFN-I) in particular in HTLV-1 pathogenesis
is still a matter of debate. ADAR1-p150 is an Interferon Stimulated Gene (ISG) induced by IFN-I that can edit viral RNAs.
We therefore investigated whether it could play the role of an anti-HTLV factor.
Results: We demonstrate here that ADAR1 is also expressed in the absence of IFN stimulation in activated primary
T-lymphocytes that are the natural target of this virus and in HTLV-1 or HTLV-2 chronically infected T-cells. ADAR1
expression is also increased in primary lymphocytes obtained from HTLV-1 infected individuals. We show that ADAR1
enhances HTLV-1 and HTLV-2 infection in T-lymphocytes and that this proviral effect is independent from its editing
activity. ADAR1 expression suppresses IFN-α inhibitory effect on HTLV-1 and HTLV-2 and acts through the repression
of PKR phosphorylation.
Discussion: This study demonstrates that two interferon stimulated genes, i.e. PKR and ADAR1 have opposite effects
on HTLV replication in vivo. The balanced expression of those proteins could determine the fate of the viral cycle in
the course of infection.
Keywords: HTLV, Interferon, ADAR1, PKRBackground
Human T-cell leukemia virus type 1 (HTLV-1) was the first
human oncoretrovirus to be discovered [1,2]. It infects 5 to
10 million people worldwide [3]. Among them, 3 to 5 per-
cent have a lifetime risk to develop a lymphoproliferative
disorder named adult T-cell leukemia (ATL) [4], or an in-
flammatory neurodegenerative disease named HTLV-1 as-
sociated myelopathy/tropical spastic paraparesis (HAM/
TSP) [5,6]. HTLV-2 infects 2 to 5 million people. Despite
similarities with HTLV-1 in its genomic organization,
HTLV-2 is only associated with rare cases of HAM/TSP-
like diseases but does not promote leukemia or lymphoma
[7,8]. The cause for such differences is a matter of investiga-
tion [9-18]. Nevertheless multiple reports already pointed
out the key roles played both by Tax and HTLV-1
antisense-encoded protein in cell transformation [18-20].* Correspondence: renaud.mahieux@ens-lyon.fr
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unless otherwise stated.Innate immunity plays a critical role in host response
to a viral infection by triggering effector mechanisms
that restrict infection [21]. Effectors of innate immunity
such as restriction factors are present in cells before in-
fection takes place and can act as immediate inhibitors
of a given infectious agent. Double stranded RNA which
is produced during replication of several viruses is a po-
tent inducer of IFN-I which then acts as a signal to in-
duce expression of antiviral effectors, among which
Adenosine Deaminase Acting on RNA (ADAR), a cellu-
lar protein which edits RNA [22]. RNA editing which
does not include capping, 3’ processing, and splicing is
defined as post-transcriptional events that modify RNA
molecules. It is a natural process used by mammal cells
to generate different variants of a given protein. ADAR
enzymes are capable of editing double stranded RNA
([23] and for a recent review see [24]). There are three
members of the mammalian ADAR family: ADAR1,
ADAR2 and ADAR3. The formers convert adenosines
into inosines, which are then translated into guanosines,Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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restricted to nervous system [25,26].
There are two ADAR1 isoforms. ADAR1-p110 is consti-
tutively expressed and found exclusively in the nucleus,
while ADAR1-p150 is an Interferon Stimulated Gene (ISG)
induced by IFN-I [27]. ADAR1-p150 is found in the nu-
cleus and in the cytoplasm [28,29]. These two isoforms are
generated from two distinct promoters and an alternative
splicing of the first exon. ADAR1-p110 and ADAR1-p150
have a C-terminal catalytic deaminase domain, three
dsRNA binding domains and one Z-DNA binding domain
in ADAR1-p110 or two in ADAR1-p150. Both ADAR1 iso-
forms edit cellular and viral RNAs possessing a double-
stranded structure [30,31]. Interestingly, several viruses pro-
duce dsRNA during their replication cycle [22].
As ADAR1-p150 expression can be induced by type I
interferon, it was anticipated that it would be an effector of
type I interferon antiviral effect on viral replication. Indeed,
viral genome editing by ADAR1 was described for several
viruses [30,32]. For example, ADAR1 edits hepatitis C viral
genome and consequently reduces the level of HCV subge-
nomic RNA [33]. ADAR1 possesses a repressive activity
against lymphocytic choriomeningitis virus (LCMV) [34],
and bovine viral diarrhea virus (BVDV) [35]. Surprisingly
however, ADAR1 plays a proviral role for other viruses such
as vesicular stomatitis virus [36,37], Kaposi sarcoma-
associated herpesvirus [38], Epstein-Barr virus [39], dengue
virus [40] and Rift valley virus [31], while controversial re-
sults on hepatitis D, measles and influenza replication have
been published [31,40-49]. ADAR1-p110 and ADAR1-p150
expression increases during the course of infection and pro-
motes HIV-1 viral replication, thus playing a proviral role
[50-53]. However, in this case, conflicting mechanisms have
also been suggested: one study suggested that this effect re-
quires ADAR1 editing activity, while another showed that
ADAR1 proviral effect is independent from its catalytic site,
but relies on the inhibition of the protein kinase R (PKR)
function, which normally inhibits mRNA translation and
induces apoptosis [50-52]. ADAR1-mediated PKR inhibi-
tion was also reported during measles virus or vesicular
stomatitis virus infection [36,37,49]. Thus, depending on
the viruses, ADARs can act either as antiviral or as proviral
factors (for recent reviews, see [30,32]).
IFN-α is being used in combination to AZT to treat ATL
patients, although the relationship between stimulation of
innate immunity and impact on HTLV cycle are still not
fully understood [21,54,55]. We recently demonstrated that
PKR prevented HTLV-1 and -2 replication in cell culture
following IFN-I treatment [11]. In another set of experi-
ments using the exquisitely sensitive 3DI-PCR technique
[56], we have also shown that HTLV-2 and simian T-cell
leukemia virus type 3 (STLV-3) genomes can be edited by
ADAR1 in cells transfected with HTLV-2 or STLV-3 mo-
lecular clones and an ADAR1-encoding plasmid [57].However we could not find such mutations in ex vivo sam-
ples obtained from HTLV-2 infected individuals, thus dem-
onstrating that ADAR1 editing of HTLV in vivo is a very
rare phenomenon and is unlikely to play an antiviral role
[57]. Though, consequences of ADAR1 expression on
HTLV replication were not fully investigated in this report.
Here, we first demonstrate that ADAR1 is expressed
in PHA/IL-2 activated primary T-lymphocytes in the ab-
sence of IFN-I stimulation, in HTLV-1 or HTLV-2
chronically infected T-cells and in primary CD4+ cells
obtained from HTLV-1 infected individuals. We show
that ADAR1 enhances HTLV-1 and HTLV-2 infection in
T-lymphocytes and that this proviral effect is independ-
ent from its editing activity. ADAR1 expression sup-
presses IFN-α inhibitory effect on HTLV-1 and HTLV-2
through repression of PKR phosphorylation. Together
with our previous results, these studies demonstrate that
two interferon stimulated genes, i.e. PKR and ADAR1
have opposite effects on HTLV replication in vivo. The
balanced expression of those proteins could determine
the fate of viral cycle in the course of infection.
Results
ADAR1 is expressed in activated peripheral blood
lymphocytes and in HTLV-1 and HTLV-2 chronically
infected T cell lines
ADAR1 was previously shown to edit the genome of some
RNA viruses and to act therefore as an antiviral factor
[31,34,44,45]. Consequently we first wondered whether
ADAR1 was expressed in primary uninfected T-lympho-
cytes that are the target of HTLV-1 and -2 retroviruses
in vivo. Given that HTLV-1 infected T-lymphocytes display
an activated phenotype [58], we first obtained Peripherical
Blood Lymphocytes (PBLs) from two healthy blood donors
and activated them with PHA and IL-2. An aliquot of the
same cells was also left quiescent. As expected, ADAR-p110
form was constitutively expressed, while ADAR1-p150 ex-
pression was induced following T-cell activation (Figure 1A).
As a control, primary B-cells were also purified from normal
PBLs and left quiescent or activated with Pansorbin for 24
and 48 hours. As observed for T-cells, B-cell activation led
to a strong increase in ADAR-1 expression (Figure 1B), thus
suggesting that increase in ADAR1 expression is linked to
cell activation.
Then, we compared the expression of both ADAR1 iso-
forms in non-infected Jurkat T-lymphocytes as well as in
HTLV-1 (C91-PL and MT2) or HTLV-2 (C19 and MO) in-
fected T-lymphocytes (Figure 1C). While ADAR1-p110 was
expressed in all transformed cells including Jurkat,
ADAR1-p150 was specifically up-regulated in HTLV-1 and
HTLV-2 chronically infected cells.
Finally, CD4+ T-cells were isolated from the blood of
two HTLV-1 infected individuals and stimulated with
PHA and IL-2 for 3 days then grown only with IL-2. For
Figure 1 (See legend on next page.)
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Figure 1 ADAR1 is expressed in activated lymphocytes as well as in HTLV-1 and HTLV-2 chronically infected T-cell lines and primary
T-lymphocytes from HTLV-1 infected individuals. (A): Whole cell extracts (60 μg) obtained from PBLs activated or not with PHA/IL-2 for 72 hours.
(B): B-cells were purified from the PBMCs of two blood donors and left unactivated (dot line) or treated with Pansorbin (solid line). ADAR1 expression
was measured 24 h and 48 h later (FACS Canto II, BD Biosciences). Isotype control is represented with a grey histogram (C): Uninfected- (Jurkat),
HTLV-1-infected (C91-PL, MT2) and HTLV-2-infected (C19, MO) cells were analyzed by western-blot analyses using anti-ADAR1 or anti-actin antibody.
(D): CD4+ T-cells from two HTLV-1 positive individuals were sorted, stimulated with PHA and cultured in the presence of IL-2. Cells were stained with
anti ADAR1 and anti HTLV p19gag antibodies followed by APC anti-rabbit and FITC anti-mouse antibodies. CD4+ cells from p19gag negative population
(dot line) or from p19gag positive population (solid line) were analyzed for ADAR1 expression. (B, D): Cells were analyzed on a FACS-Canto II
(BDSciences) collecting 100 000 events. Results analyzed using FlowJo software.
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flow cytometry in the fraction of CD4+ cells that express
HTLV-1 (p19gag) antigen and compared to the p19gag
negative population. Interestingly, HTLV-1 productively
infected cells expressed higher levels of ADAR1 than
cells that were also stimulated but did not express
HTLV-1 antigens (Figure 1D).
Altogether, these results show that both isoforms of
ADAR1 are expressed in the absence of IFN-I stimulation
in activated T-cells that are susceptible to HTLV-1 and
HTLV-2 infection. They also demonstrate that HTLV-1 and
HTLV-2 chronically infected cells express the inducible
ADAR1 isoform and suggest that HTLV-1 expression is
correlated with an increased ADAR1 expression in primary
CD4+ T-cells.
ADAR1 has a proviral effect on de novo HTLV-1 and
HTLV-2 infection in T- lymphocytes
Then, we investigated the effect of ADAR1 expression
on de novo infection of T-cells with HTLV-1 and HTLV-
2 using a previously described protocol (Figure 2A) [11].
HTLV-1/-2 infection occurs mainly through cell-cell
contact. Target Jurkat (Figure 2B, C) or primary PBLs
(Figure 2D, E) were therefore co-transfected with a plasmid
encoding ADAR1 and a plasmid encoding the luciferase in-
dicator gene under the control of the HTLV-1 or HTLV-2
LTR promoters. Twenty-four hours later, target cells were
co-cocultured with gamma-irradiated C91-PL (HTLV-1),
C19 (HTLV-2) donor cells or non-infected Jurkat cells. The
viral non-structural Tax protein is necessary for activating
transcription from the LTR. Consequently, luciferase activity
monitors viral infection i.e. viral entry, reverse transcription,
integration and viral expression in target cells (Figure 2A).
ADAR1 expression in target Jurkat cells significantly en-
hanced luciferase activity after co-culture with HTLV-1 or
HTLV-2 infected irradiated T-cells (Figure 2B compare
lane 3 vs. 4, and Figure 2C lane 3 vs. 4). These results
suggest that ADAR1 increases target cells susceptibility to
HTLV-1 and HTLV-2 infection. As a control, ADAR1
did not affect the level of luciferase activity in target Jurkat
target cells co-cultured with non-infected T-cells (Figure 2B
and C lanes 1-2).
Similar experiments were then performed using pri-
mary PBLs obtained from healthy blood donors as targetcells, instead of Jurkat cells. As in Jurkat, ADAR1 ex-
pression in PBLs was associated with an increased lucife-
rase activity (Figures 2D and E compare lane 2 vs. 4). To
control that luciferase activity was linked to viral infection
and not a passive Tax transfer from donor to target cells,
we performed a series of control experiments where PBLs
were treated or not with AZT, an inhibitor of reverse tran-
scription. As expected, AZT treatment strongly reduced
luciferase activity thus demonstrating that de novo Tax
synthesis is required in the target cells (Figure 2D and E,
lanes 2 vs.3).
These results demonstrate that ADAR1 has a proviral
effect on HTLV-1 and HTLV-2 de novo infection both in
T-cell lines and in primary T- lymphocytes.
ADAR1 increases HTLV-1 and HTLV-2 protein expression
To decipher how ADAR1 affects HTLV-1/2 replication,
Jurkat (Figure 3A-B) or primary T-lymphocytes (Figure 3C-
D) were transfected with molecular clones which contain
full length proviruses together with HTLV-1 or HTLV-2-
LTR-luciferase reporter, in the presence or absence of
ADAR1. This system allows us to bypass the entry-
integration viral steps cells. In both settings, ADAR1 ex-
pression was associated with an increased luciferase activity,
thus indicating up-regulation of Tax1 and Tax2 protein ex-
pression (Figure 3A-D compare lane 2 and 3). Of note, in
the presence of ADAR1 plasmid, a higher increase in lucif-
erase activity was observed when Jurkat cells were trans-
fected with the HTLV-1 molecular clone than with the
HTLV-2 clone. This effect was not observed in primary T-
cells.
293T-LTR-GFP cells were then transfected with
HTLV-1 or HTLV-2 molecular clones. These cells stably
harbor a GFP reporter gene whose expression parallels
activation of LTR-driven transcription. Consistent with
co-culture experiments, ADAR1 expression increased
the number of GFP positive cells, thus demonstrating an
increased Tax-mediated LTR transcription (Figure 3E
compare minus and plus ADAR1). ADAR1 expression
was also associated with an increased number of synci-
tia, indicative of a higher HTLV envelope protein ex-
pression (Figure 3E, compare minus and plus ADAR1).
In addition, most GFP positive cells were also strongly
positive for ADAR (Figure 3F). Western-blot analyses,
Figure 2 ADAR1 has a proviral effect on de novo HTLV-1 and HTLV-2 infection in T-lymphocytes. (A): Jurkat or PBLs were transfected either
with 2.5 μg of an ADAR1 or of a backbone vector, together with 2.5 μg of a plasmid encoding the luciferase gene under the control of the HTLV-1-LTR
or HTLV-2-LTR. Twenty-four hours later, Jurkat (B, C) or PBLs (D, E) were co-cultured with (B, D) irradiated C91-PL (HTLV-1), (C, E) C19 (HTLV-2) or (B, C,
D, E) Jurkat (non-infected) cells for 24 hours. Luciferase activity was measured, and results normalized by protein concentration as determined by the
Bradford method and calculated as fold change compared to infected cells transfected with the control plasmid arbitrarily set to 100%. (D, E): PBLs
were treated with AZT (50 μM) before the co-culture with C91-PL or C19 irradiated cells. (B, C): Data are the mean ± standard deviation (SD) from 3
independent experiments. Asterisks indicate statistically significant differences between treated and untreated cells (paired Student t test, *p < 0.05;
**p < 0.01). (D, E): Data are representative of two different experiments obtained with two different blood donors.
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constant amount of HTLV-1 (Figure 3G) or HTLV-2
molecular clone (Figure 3H) and increasing amounts of
ADAR1 confirmed those observations. Indeed, both
Tax1, Tax2 and p24gag protein expression levels in-
creased in a dose dependent manner (Figure 3G-H). As
a control, actin levels remain constant under the same
conditions. The amount of p19gag in the culture super-
natant, which is assumed to reflect the quantity of viral
particles, was also measured in the same experimental
conditions. Consistent with western-blot results, p19gagin the supernatant also increased in a dose-dependent
manner (Figure 3I, J).
Thus, these results demonstrate that ADAR1 increases
viral expression and viral production in all cell lines
tested.
ADAR1 expression does not impair the production of
infectious viral particles
Given that ADAR1 possesses an editing activity, we then
wondered whether viral particles produced in the pres-
ence of ADAR1 were infectious or not. 293T cells were
Figure 3 ADAR1 expression enhances HTLV-1 and HTLV-2 protein expression. (A, B): Jurkat or (C, D) PBLs were transfected with (A, C)
2 μg of pACH or (B, D) pH6neo molecular clones together with 1 μg of a plasmid encoding ADAR1 and 2 μg of (A, C) HTLV-1-LTR or (B, D)
HTLV-2-LTR-luc plasmids. Forty-eight hours later, luciferase activity was measured and results normalized by protein concentration as determined
by the Bradford method and calculated as fold change compared to cells that were not transfected with ADAR1 plasmid arbitrarily set to 100%.
(A, B): Data are the mean ± standard deviation (SD) from 3 independent experiments. Asterisks indicate statistically significant differences between
treated and untreated cells (paired Student t test, *p < 0.05). (C, D): Data are representative of two different experiments obtained with two
different blood donors. (E, F): 293T-LTR-GFP cells were transfected with 1 μg of pACH (HTLV-1) or pH6neo (HTLV-2) molecular clones together with
125 ng of an ADAR1 expression plasmid or of the backbone vector. Forty-eight hours later, cells were visualized and pictures taken with a Zeiss Axio
Vert.A1 imaging microscope. (G, H, I, J): 293 T cells were transfected with 4 μg of (G, I) pACH (HTLV-1) or (H, J) pH6neo (HTLV-2) molecular clones and
increasing amount (0, 5, 50, 500 ng) of an ADAR1 expression plasmid. (G, H): Western blot analyses were performed on 60 μg of proteins obtained
from whole cell extracts using anti-ADAR1, anti-p24gag, anti-Tax1, anti-Tax2 and anti-actin antibodies. (I, J): p19gag was quantified in the culture
supernatants from cells transfected as in (G, H). Data are represented as fold change compared to the p19gag values obtained for cells that were not
transfected with the ADAR1 plasmid arbitrarily set to 100%.
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and increasing amount of ADAR1 plasmid. Forty-eight
hours after transfection culture medium was removed,
cells were extensively washed before being co-cultured
with Jurkat-LTR-luciferase cells (Figure 4A). We ob-
served a dose-dependent increase in luciferase activity,
suggesting that viral particles that are made in thepresence of ADAR1 are still capable of replication in
their target cells (Figure 4B, C). To control that lucifer-
ase activity measured in Jurkat target cells was not due
to a passive Tax transfer from the transfected cell to the
target cell, 293-T cells were transfected with Tax1 or
Tax2 plasmids and co-cultured with Jurkat-LTR-
luciferase cells. Luciferase activity was measured and
Figure 4 ADAR1 expression does not affect viral infectivity. (A): 293-T cells were transfected with 4 μg of (B) pACH or (C) pH6neo molecular clones
and increasing amount (0, 5, 50, 500 ng) of an ADAR1 expression plasmid or 8 μg of (D) pSG5M-Tax1, (E) pSG5M-Tax2 or backbone vector. Forty-eight
hours later, cells were washed and co-cultured with Jurkat-LTR-luc cells for 24 hours (ratio 1:3). Luciferase activity results were normalized to protein
concentration as determined by the Bradford method and calculated as fold change compared to cells non transfected with ADAR1 plasmid arbitrarily set
to 100%. Data are the mean ± standard deviation (SD) from 3 independent experiments. Asterisks indicate statistically significant differences between
treated and untreated cells (paired Student t test, *p < 0.05; ***p < 0.001; NS: non significant).
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backbone vector (Figure 4D, E).
Altogether, these results demonstrate that ADAR1 has
a proviral effect, enhances HTLV-1/-2 expression and re-
lease of infectious particles.
ADAR1 proviral effect is independent from its editing
activity
We next wondered whether ADAR1 proviral effect was
dependent or not of its editing activity. Using a previously
described ADAR1 RNA editing reporter system [40], we
first verified that the plasmid encoding ADAR1 with a mu-
tation in its catalytic site was deficient for its editing activ-
ity. The unedited reporter plasmid contains a stop codon
that is converted into Trp codon when A to I editing by
ADAR1 occurs. As a consequence, editing by ADAR1 is
correlated with Firefly luciferase expression. As expected,transfection of wild-type ADAR1 induced an increased lu-
ciferase activity (Additional file 1: Figure S1 left graph),
while ADAR1 mutant did not lead to any increase in lucif-
erase expression (Additional file 1: Figure S1 right graph).
Then, 293-T cells were transfected with HTLV-1 or
HTLV-2 molecular clones, in the presence of plasmids en-
coding either wild-type ADAR1 or the editing-deficient
ADAR1 mutant. p24gag western-blot (Figure 5A, B) or
p19gag ELISA (Figure 5C, D) revealed that expression of
both wild-type or mutant ADAR1 led to a similar increase
in viral protein expression and virus release.
Next, to confirm that editing has no effect on HTLV
transcription, we used Jurkat cells transfected with the
HTLV-LTR-luciferase reporter plasmids and co-transfected
with HTLV-1 or HTLV-2 molecular clone, together with
wild-type or editing-deficient ADAR1 constructs (Figure 5E,
F). A similar increase in luciferase activity was observed with
Figure 5 ADAR1 enhances HTLV-1 and HTLV-2 replication independently from its editing activity. 293-T cells were transfected with (A, C) 4 μg of
pACH or (B, D) pH6neo molecular clones together with 500 ng of a plasmid coding for ADAR1 wild-type or for an editing-deficient ADAR1 protein (ADAR1
mutant). (A, B): Western blot analyses were performed on 60 μg of proteins obtained from whole cell extracts using anti-p24gag, anti-ADAR1 and anti-actin
antibodies. (C, D): p19gag was quantified in supernatant obtained from cells transfected as in (A, B). Data are represented as fold change compared to the
p19gag values obtained for cells that were not transfected with the ADAR1 plasmid arbitrarily set to 100%. (E, F): Jurkat cells were transfected with 2 μg of
(E) pACH or (F) pH6neo molecular clones, together with 1 μg of a plasmid encoding either ADAR1 wild-type or ADAR1 mutant and 2 μg of (E) HTLV-1-LTR
or (F) HTLV-2-LTR-luc plasmid. Forty-eight hours later, luciferase activity was measured and results normalized to protein concentration as determined by the
Bradford method and calculated as fold change compared to cells non transfected with ADAR1 plasmid arbitrarily set to 100%. (C-F): Data are the mean ±
standard deviation (SD) from 3 independent experiments. Asterisks indicate statistically significant differences between treated and untreated cells (paired
Student t test; NS: non significant).
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viral particles produced in the presence of both wild-type or
mutant ADAR1 plasmids were infectious by performing a
coculture assay as described in Figure 2A. ADAR1 mutant
expression increased the release of infectious viral particles
similarly to ADAR1 wild-type both in HTLV-1 and HTLV-2
settings (Additional file 2: Figure S2).
Altogether, these results confirm that ADAR1 proviral
effect on HTLV-1 and HTLV-2 replication is independ-
ent from its editing activity.ADAR1 proviral effect is mediated through inhibition of
PKR activation
PKR is an ISG that has been shown to be involved, once ac-
tivated by phosphorylation, in a signaling pathway leading
to inhibition of mRNA translation. It was previously esta-
blished that ADAR1 antagonizes PKR activation [37,49].
This effect requires double-strand RNA binding of ADAR
[37]. We therefore wondered whether ADAR1 proviral
effect on HTLV-1 and HTLV-2 could be mediated through
PKR inhibition. To test this hypothesis, PKR western-blots
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cells transfected with HTLV-1 and HTLV-2 molecular
clones together with increasing amount of ADAR1
(Figure 6A, B). Consistent with results presented above, the
amount of p24gag and Tax viral proteins increased in an
ADAR1 dose dependent manner, while the level of PKR
remained constant (Figure 6A, B compare lane 1 vs 2-4).
Interestingly, the level of phospho-PKR (i.e. the active form
of PKR) was inversely correlated with that of ADAR1
(Figure 6A, B, compare lane 1 and 4).
To demonstrate that ADAR1 proviral effect was linked
to the inhibition of PKR activation, cells were transfected
either with PKR siRNA or with control siRNA before be-
ing transfected with HTLV-1/2 molecular clones and
ADAR1 plasmid (Figure 6C, D). As previously described
[11], PKR extinction results in an increased p24 expres-
sion. However, despite ADAR1 ectopic expression, the
level of p24gag remained constant, in cells transfected
with PKR siRNA, while it increased when control siRNA
were transfected.Figure 6 ADAR1 proviral effect is mediated through inhibition of PKR act
molecular clones and increasing amount (0, 5, 50, 500 ng) of ADAR1 plasmid. W
whole cell extracts using anti-ADAR1, anti-p24gag, anti-Tax1, anti-Tax2, anti-PKR, a
transfected with siRNA directed against PKR (20nM) or with control siRNA. Twelv
with 1.2 μg of (C) pACH, (D) pH6neo and 125 ng of an ADAR1 expression plasm
from whole cell extracts using anti-ADAR1, anti-p24gag, anti-PKR, anti-phospho-PThese results demonstrate that ADAR1 effect on HTLV-1
and HTLV-2 is linked to the inhibition of PKR phosphory-
lation. A previous study demonstrated that HIV-1 Tat inter-
acts with PKR and inhibited PKR auto-phosphorylation thus
providing a possible mechanism of IFN suppression [59].
We therefore tested whether Tax could also bind and inhibit
PKR. However no interaction between Tax and PKR was ob-
served (data not shown).ADAR1 expression reverses IFN-α inhibitory effect on
HTLV-1 and HTLV-2
We have recently shown that IFN-α restricts HTLV-1 and
HTLV-2 de novo infection by inhibiting viral protein syn-
thesis through PKR activation [11]. Since ADAR1 inhibits
PKR activation and enhances viral protein translation, we
finally wondered whether IFN-α still had an antiviral effect
in the presence of ADAR1 ectopic expression.
293-T cells were transfected with HTLV-1 (Figure 7A) or
HTLV-2 molecular clones (Figure 7B), with or without anivation. 293-T cells were transfected with 4 μg of (A) pACH or (B) pH6neo
estern blot analyses were performed on 60 μg of proteins obtained from
nti-phospho-PKR and anti-actin antibodies. (C, D): 293-T cells were
e hours later cells were transfected with 20nM of the same siRNA together
id. Western blot analyses were performed on 60 μg of proteins obtained
KR and anti-actin antibodies.
Figure 7 ADAR1 expression reverses IFN-α inhibitory effect on
HTLV-1 and HTLV-2. 293–T cells were transfected with 4 μg of (A) pACH
or (B) pH6neo molecular clone. When required, 500 ng of an ADAR1
expression plasmid were also transfected and cells were treated with
increasing amount of IFN-α (0-1000 U/mL) for 48 hours. Western blot
analyses were performed on 60 μg of proteins obtained from whole cell
extracts using anti-ADAR1, anti-p24gag, anti-Tax1, anti-Tax2, anti-PKR,
anti-phospho-PKR and anti-actin antibodies.
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increasing amounts of IFN-α. In the absence of ADAR1
over-expression and consistent with our previous data [11],
IFN-α treatment led to a decreased p24gag as well as Tax1
or Tax2 protein expression (Figure 7A and B, compare lane
1 and 4). This effect was correlated with an increase in PKR
and phospho-PKR levels. In the presence of ectopic
ADAR1, IFN-α treatment still lead to increased PKR levels,
but the levels of phospho-PKR remained low and were not
associated with a decreased p24gag or Tax expression
(Figure 7A and B, compare lane 5 and 6-8).These results show that IFN-α cannot activate PKR in
the presence of elevated levels of ADAR1, thus ADAR1
expression prevents PKR from having its antiviral role.
Discussion
ADAR1 is responsible for A-to-G (I) editing of cellular and
viral genes [30,31]. Editing can be site-selective in the case
of Hepatitis virus D [41,42] or of L-glutamate receptor [60].
It can also be non-selective in the case of Hepatitis C, influ-
enza, measles and Rift valley viruses [31,33,44]. As ADAR1
expression is induced by IFN-I, it was originally anticipated
that IFN-I antiviral effects occur at least partly through an
ADAR1 dependent editing of viral genomes. Indeed, Taylor
et al. demonstrated that IFN-α treatment induces A-to-I
editing in HCV replicon cells, while HCV editing is re-
duced when ADAR1 enzymatic activity is inhibited [33].
We previously demonstrated that co-transfecting ADAR1
together with HTLV-2 or STLV-3 molecular clones in
293-T cells led to A-to-G editing although the frequency of
such editing could not be quantified [57]. A similar obser-
vation was made for measles and influenza viruses [44].
However, such hyper-edited sequences were only detected
using the exquisitely sensitive 3DI-PCR technique [31], and
replication of those viruses was not tested. In addition, edi-
ting was not observed in a series of samples obtained from
20 HTLV-2 infected individuals, although ADAR1 mRNA
was present in those samples. This suggested that A-to-G
(I) editing is an extremely rare phenomenon in vivo, at least
in HTLV-2 infected cells [57].
As HTLV-1 mostly infects CD4+ T-lymphocytes and
HTLV-2 infects CD8+ T-lymphocytes [16], we measured
here ADAR1 p110 and p150 expression in peripheral
blood lymphocytes that were left quiescent or PHA/IL-2
activated. Consistent with a previous study [61], both
ADAR1 isoforms were present in activated lymphocytes.
Thus, ADAR1 is expressed in cells that are targets of
HTLV-1 and HTLV-2. Consistent with data obtained on
HTLV-2 ex vivo samples [57], we have also shown that
ADAR1 expression is higher in HTLV-1 and HTLV-2
chronically infected lymphocytes compared to non-
infected T-cells and in primary CD4+ T-cells obtained
from HTLV-1 infected individuals, thus suggesting that
ADAR1 is expressed in response to HTLV infection.
Interestingly, Clerzius et al have also shown that
ADAR1-p110 and ADAR1-p150 expression is increased
when Jurkat cells are infected with HIV-1 [50]. It could
be of interest to determine in the future which factor in-
duces ADAR1 expression in HTLV-1/-2 infected cells.
ADAR1 proviral effect was previously observed for diffe-
rent viruses [36,37,40,49-52]. This effect is mediated through
(1) viral RNA editing, (2) the inhibition of PKR through the
formation of an ADAR1/PKR complex [37,50] or (3) an in-
crease in ADAR1 catalytic activity. We have shown here that
ADAR1 effect on HTLV-1/-2 replication is independent
Cachat et al. Retrovirology 2014, 11:93 Page 11 of 15
http://www.retrovirology.com/content/11/1/93from ADAR1 editing activity and is rather linked to the in-
activation of PKR function. It could also be of interest to de-
termine whether ADAR1 effect is also linked to the
formation of a complex between those two cellular proteins.
Of note, our results do not exclude the fact that ADAR1
editing on HTLV-1/2 genomes might also occur, but at a
very low frequency thus having no deleterious effect on viral
cycle.
Shoggins et al have recently developed an assay to
study the effect of hundreds of ISG products on different
viruses that belong to Flaviviridae (YFV, WNV), Toga-
viridae (CHIKV, VEEV) or Retroviridae (HIV-1) [53].
This led to the identification of ISGs that are strong re-
pressors, modest inhibitors, but also that are activators
of viral cycle. In this study, ADAR was identified as an
enhancer of replication for all viruses tested. Interest-
ingly, the authors also tested the combination of one in-
hibitory and one enhancing ISG on viral cycle, and
showed that, in most cases, viral replication was more
influenced by the inhibitory than by the enhancing ISG
[53]. Thus, this study highlighted that IFN-I does not
necessarily promote an antiviral state and that a subtle
balance between repressor and activator ISGs regulate
the fate of viral infections.
We have previously shown that IFN-α inhibits HTLV-1
and HTLV-2 de novo infection through PKR activation
[11]. We demonstrated here that another ISG, ADAR1
p150 is expressed in activated T-cells and plays a proviral
role on HTLV-1 and HTLV-2 replication. We can therefore
elaborate a working hypothesis that, during primary infec-
tion and in the absence of IFN-I, HTLV-1/-2 will infect cells
that express ADAR1 p150 but not PKR. In this case,
ADAR1 will play a proviral role. Infection could then lead
to IFN-I production that could in turn activate both PKR
and ADAR-1 p150 in surrounding cells. In this case, ac-
cording to Schoggins et al., PKR could play an antiviral role
[53]. Given that IFN-I is used to treat chronic ATL patients
[62], it would therefore be interesting to measure quantita-
tively the expression of both PKR and ADAR in ATL cells
if those samples were available.
Conclusions
In conclusion, our results demonstrate that IFN-I pro-
motes the expression of two ISG that have antagonist
roles on HTLV replication.
Methods
Cell culture and flow cytometry
293T and 293T-LTR-GFP cells were maintained in
Dulbecco’s modified Eagle’s medium (DMEM) supple-
mented with 10% fetal bovine serum (Gibco, Life technolo-
gies) and 100 μg/mL penicillin-streptomycin (Gibco, Life
technologies). Jurkat, Jurkat-LTR-luc, HTLV-1- (C91/PL,
MT2) and HTLV-2-infected T-cell lines (C19, MO), weremaintained in RPMI 1640 medium supplemented with 10%
fetal bovine serum (Gibco, Life technologies) and 100 μg/
mL penicillin-streptomycin (Gibco, Life technologies). Peri-
pheral blood lymphocytes (PBL) were purified from blood
samples obtained from healthy donors (Etablissement Fran-
çais du Sang, Lyon) or from HTLV-1 infected individuals.
HTLV-1 infected blood samples were obtained in the con-
text of a Biomedical Research Program approved by the
"comité de protection des personnes", Ile de France III,
Paris (2007-A01103-50, number 2494) with informed con-
sent of all individuals. Cells maintained in RPMI 1640
medium supplemented with 10% fetal bovine serum
(Gibco, Life technologies) and 100 μg/mL penicillin-
streptomycin (Gibco, Life technologies). PBL were either
left quiescent or stimulated with phytohemagglutinin
(PHA, 1 μg/mL, SIGMA) and interleukin-2 (IL-2 at 150 U/
mL). When required, IFNα-2a (Tebu-Bio) was added for
3 days to the cells. 293T-LTR-GFP and Jurkat-LTR-luc are
stably transfected with a plasmid encoding GFP (green flo-
rescent protein) or luciferase under the control of HTLV-1
long terminal repeat (LTR), respectively [63,64]. All cell
lines were grown at 37°C in 5% CO2.
B-cells analyses
CD19+ B cells were purified by depletion/negative selec-
tion using a B-cell isolation kit (Miltenyi Biotech). Purity
of isolated B-cells was monitored using anti-hCD19
VioBlue (Miltenyi Biotech) and was analyzed by
fluorescence-activated cell sorting (FACS CantoII; BD
Biosciences).
B-lymphocytes were cultured in RPMI 1640 medium
(Gibco BRL Invitrogen) supplemented with 10% FCS
and 1% penicillin/streptomycin with 50 ng/ml IL2 (Mil-
tenyi Biotech). They were either treated with Pansorbin
200 ng/ml (Millipore Calbiochem) (activated condition)
or left untreated (non activated condition). 24 h and
48 h later cells were labeled with hCD19-PE, hCD3-PE
and hCD69-PEvio770 (Miltenyi Biotech). ADAR anti-
bodies (Abcam) were used after permeabilization/
fixation using the Cytofix/Cytoperm kit (BD).
T-cells analyses
CD4+ T-cells obtained from healthy donors or HTLV-1
infected individuals were purified by depletion/negative
selection using T-cell isolation kit (Miltenyi Biotech).
Purity of CD4+ T-cells was monitored using anti-
hCD4APC antibodies (Miltenyi Biotech) and was analyzed
by fluorescence-activated cell sorting (FACS CantoII; BD
Biosciences). CD4+ T-lymphocytes were then cultured at
1.106/ml with IL-2 (150 U/ml) and PHA (1 μg/ml) for
3 days and then maintained only with IL-2 for 5 days. Cells
were analyzed with a surface staining against hCD4-APC
and hCD69-PE (Miltenyi Biotech) or intracellular staining
for ADAR and p19 (Zeptometrix) after permeabilization/
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lyzed on a FACS-Canto II (BD Sciences) collecting 100.000
events. Results were analyzed using the FlowJo software.
Plasmids
HTLV-1 proviral DNA clone (pACH) was provided by Dr L.
Ratner [65]. HTLV-2 proviral DNA clone (pH6neo) and
SV2Neo plasmids were provided by Dr P. Green [66].
pSG5M-Tax1, pSG5M-Tax2, HTLV-1- and HTLV-2-LTR-lu-
ciferase plasmids were previously described [15,67]. ADAR1
wild type and editing-deficient (HAE - >HAG mutation at
the position 912) [68] were provided by Dr P. Auewarakul
[52]. The 3XF-ADAR1 RNA editing reporter system was
provided by Dr. V. Lotteau [40]. PKR wild-type plasmid was
provided by Dr E. Meurs [69]. Optineurin wild-type plasmid
was previously described [70].
Cell-to-cell infection experiments
Jurkat (106) or PBLs (5.105) were transfected with 2.5 μg of
the HTLV-1 or the HTLV-2-LTR-luciferase plasmids and
2.5 μg of the ADAR1 plasmid (Neon® Transfection System,
Invitrogen) following the manufacturer’s instructions.
Twenty-four hours later, they were co-cultured with irradi-
ated (77 Gy CIS, BIO international, IBL 637) C91-PL or
C19 cells (3:1 ratio). When needed, PBLs were treated with
50 μM AZT (Sigma) 24 hours and 3 hours before infection.
Twenty-four hours later, reporter activity was assayed
(Luciferase reporter assay system, Promega). Luciferase ac-
tivity was normalized by protein concentration as deter-
mined by the Bradford method (Bio-Rad).
293T (3.106) cells were seeded onto 100 mm dishes.
Twenty-four hours later, cells were transfected with 4 μg of
HTLV-1 (pACH) or HTLV-2 (pH6neo) molecular clones
and increasing amount (0, 5, 50, 500 ng) of ADAR1 expres-
sion plasmid (Polyfect, Qiagen). Forty-height hours post-
transfection, 293 T cells were washed and co-cultured with
reporter Jurkat-LTR-Luciferase (1:3 ratio) cells for 24 hours.
Reporter activities were assayed using the luciferase reporter
assay system (Promega) and normalized by protein concen-
tration as determined by the Bradford method (Bio-Rad).
Transfections with HTLV molecular clones
293T cells (3.106) were seeded onto 100 mm dishes. The
following day, 4 μg of pACH (HTLV-1), pH6neo
(HTLV-2) or SV2Neo (control) plasmids were trans-
fected with or without 5, 50, 500 ng of ADAR1 using
PolyFect reagent (Qiagen) following manufacturer's in-
structions and cells were treated with increasing
amount (0, 10, 100, 1000 U/mL) of IFN-α2a (Tebu-Bio)
for 48 hours. Reporter activity was assayed (Luciferase
reporter assay system, Promega) and normalized by pro-
tein concentration as determined by the Bradford
method (Bio-Rad).Jurkat cells (106) or PBL (5. 105) were transfected with
2 μg of the HTLV-1 or the HTLV-2-LTR-luciferase plas-
mids, 2 μg of the HTLV-1 (pACH) or HTLV-2 (pH6neo)
molecular clones with or without 1 μg of the ADAR1 ex-
pression plasmid (Neon® Transfection System, Invitrogen)
following manufacturer’s instructions. Forty-eight hours
later reporter activity was assayed (Luciferase reporter assay
system, Promega). Luciferase activity was normalized by
protein concentration as determined by the Bradford
method (Bio-Rad).
Fluorescence microscopy
293T-LTR-GFP cells were seeded at 5. 105 cells/well on 6-
well plates. The next day, one microgram of the appropriate
plasmid was transfected as described above, with or without
the ADAR plasmid. Two days later, cells were visualized
and pictures were captured with a Zeiss Axio Vert.A1 im-
aging microscope.
p19gag ELISA
Cell culture supernatants were collected 48 hours post-
transfection and the presence of the HTLV matrix p19gag
protein was quantified using a commercially available
ELISA kit (Retrotek HTLV-1/2 p19 antigen, Zeptometrix)
following the manufacturer’s instructions as previously de-
scribed [11]. In brief, wells are coated with polyclonal anti-
bodies which react with the major gag gene products of
HTLV-1 and HTLV-2. Viral antigen in the test specimen is
captured by the antibody.
PKR silencing
293T cells were seeded at a concentration of 3.105 cells per
well onto 6-well plates. The following day, 20 nM of PKR
siRNA (ON-TARGETplus SMART pool EIF2AK2, Fermen-
tas) or control siRNA (ON-TARGETplus Non-targeting
Pool, Fermentas) were transfected (HiPerfect reagent,
Qiagen) as previously described [11]. Twelve hours post-
transfection, 1.2 μg of pACH or PH6neo plasmid were
transfected together with 20 nM of siRNA and 125 ng of
ADAR1 (Attracten reagent, Qiagen) following the manufac-
turer's instructions. Cells were collected 48 hours later and
analyzed.
Tax Ni-NTA immunoprecipitation
293T cells were seeded in 10-cm dishes and transfected
(Polyfect, Qiagen) with a Tax1-His-encoding plasmid
(4 μg), together with an OPTN- or a PKR-encoding plas-
mid (4 μg). Twenty-four hours later, cells were harvested
and lysed in Chris buffer (50 mM Tris, 0.5% Nonidet P-40,
200 mM NaCl, 0.1 mM EDTA, 100 mM NaF, 2 mM
Na3VO4, 10 mM imidazole) in the presence of protease in-
hibitors (Complete, Roche Diagnostics) and incubated with
Ni2+-NTA (nitrilotriacetic acid) beads (Sigma) at +4°C
under agitation. Beads were then washed extensively in
Cachat et al. Retrovirology 2014, 11:93 Page 13 of 15
http://www.retrovirology.com/content/11/1/93Chris buffer. Bound proteins were eluted in Laemmli buffer
and processed for immunoblot analyses. The following anti-
bodies were used: anti-His (sc-804, Santa Cruz), anti-OPTN
(#100 000, Cayman Chemical), anti-PKR (71/10, [71]).
Immunoblot analyses
Cells were washed with PBS, lysed (50 nM Tris-HCl
pH 7.4, 150 nM NaCl, 5 mM EDTA, 0.5% Nonidet-P-40,
0.2 mM Na3VO4, 50 mM NaF, 1 mM dithitheitol, 1 mM
phenylmethylsulfonyl fluoride) and protease inhibitors
(Complete Roche Applied Science) as previously described
[67]. Cell debris were pelleted by centrifugation. Protein
concentration was determined by the Bradford method
(Bio-Rad). Sixty micrograms of proteins were loaded onto
4-12% NUPAGE gels (NOVEX, Invitrogen), subjected to
electrophoresis at 150 V, and transferred onto a PVDF
membrane (Immobilon-P, Millipore). Membranes were
blocked in a 5% milk-PBS-0.05% Tween 20 solution, then
incubated overnight with the primary antibody (anti-
ADAR1 (Abcam ab88574, 1:1000), anti-PKR 71/10 (1:500)
[71], anti-phospho PKR (Epitomics #1120-1, 1:2000), anti-
Tax-1-specific (Tab 172, 1:1000), anti-Tax-2 (GP3738,
1:4000), [17] anti-HTLV-1/2 p24 (Zeptometrix 75/4.21.11,
1:400), anti-β-actin clone AC74 (Sigma, 1:40000). The next
day, membranes were washed and incubated either with
anti-rabbit or with anti-mouse horseradish peroxidase-
conjugated secondary antibodies and developed using ECL
Plus reagent kit (GE Healthcare).
Additional files
Additional file 1: Figure S1. Testing the editing capacity of ADAR1wt
and ADAR1 mutant constructs. 293-T cells were transfected with 150 ng
of the 3XF-ADAR1 RNA editing reporter system with (left) 0, 150, 300, 600,
1000 ng of the plasmid coding for ADAR1 wild-type or with (right) 0, 150,
300, 600, 1000 ng of the plasmid encoding ADAR1 with a mutation in its
catalytic site. Forty-eight hours later, luciferase activity was measured and
results normalized to renilla expression and calculated as fold change
compared to cells non transfected with ADAR1 plasmid arbitrarily set to
100%. Data are the mean ± standard deviation (SD) from 2 independent
experiments. Asterisks indicate statistically significant differences between
treated and untreated cells (paired Student t test, *p < 0.05; NS: non
significant).
Additional file 2: Figure S2. Viral particles produced in the presence of
an editing-deficient ADAR1 are still infectious. 293-T cells were transfected
with 4 μg of (A) ACH or (B) pH6neo molecular clone together with
500 ng of wild type or mutant ADAR1. Forty-eight hours later, cells were
washed and co-cultured with Jurkat-LTR-luc cells for 24 hours (ratio 1:3).
Luciferase activity was normalized by protein concentration as
determined by the Bradford method and calculated as fold change
compared to cells non transfected with ADAR1 plasmid arbitrarily set to
100%. Paired Student t test, NS: not significant.
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